Patents Examined by Kristin A Vajda
  • Isocyanate production method
    Patent number: 11306055
    Abstract: An isocyanate production method is characterized by having: a carbamation step in which a carbonic acid ester, an inorganic acid salt of an amino acid derivative, and a basic compound are reacted to obtain a reaction mixture containing a carbamic acid ester derived from the carbonic acid ester, a hydroxy compound derived from the carbonic acid ester, and the carbonic acid ester; and a thermal decomposition step in which the carbamic acid ester is subjected to a thermal decomposition reaction to obtain an isocyanate.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: April 19, 2022
    Assignee: ASAHI KASEI KABUSHIKI KAISHA
    Inventors: Nobuhisa Miyake, Yuji Kosugi, Yusuke Sakurai, Masaaki Shinohata
  • Magnesium compositions and methods of use
    Patent number: 11298330
    Abstract: The present invention provides a method of administering magnesium threonate to a subject in need of supplementing magnesium. At least a portion of magnesium (Mg) and threonate (T) is present in a salt form of MgT2. The method may comprise administration of magnesium threonate at two different time points per day. The method may comprise administering, at a first time point, a first oral dosage form comprising magnesium threonate. The method may comprise administering, at a second time point, a combination of the first oral dosage form and a second oral dosage form comprising magnesium threonate. The first and second oral dosage forms may exhibit different dissolution profiles in a dissolution medium.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 12, 2022
    Assignee: Neurocentria, Inc.
    Inventors: Guosong Liu, Fei Mao, Jason Weinger
  • Ophthalmic compositions of brinzolamide
    Patent number: 11298360
    Abstract: The present invention relates to an aqueous ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, the solution comprising at least 0.5 w/v % brinzolamide dissolved in the solution; hydroxy-propyl-?-cyclodextrin; polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and water and/or the process for preparation thereof.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: April 12, 2022
    Inventors: Saraganachari Andanayya, Narayanaswamy Abhilash, Sreenivasa Reddy, Shivakumar Pradeep
  • Preparation method of a cyclic phosphonate compound
    Patent number: 11292805
    Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: April 5, 2022
    Assignee: GANNEX PHARMA CO., LTD.
    Inventors: Jinzi Jason Wu, Bailing Yang, Bin Liang
  • Process for preparing aminopyrimidine derivatives
    Patent number: 11286253
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: March 29, 2022
    Assignee: Yuhan Corporation
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Oxysterols and methods of use thereof
    Patent number: 11279730
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3 and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 22, 2022
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin, Daniel La
  • Method of regulating immunity in the intestines
    Patent number: 11278507
    Abstract: Methods for stimulating the G protein receptor (Gpr91) pathway in intestinal cells to release IL-25 and enhance a type II immune response in the subject are useful in the treatment or prevention of bacterial or parasitic infection. Similarly methods and compositions used therein to inhibit or stimulate GPR91 are useful for the treatment or inhibition of certain diseases, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Crohn's disease.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: March 22, 2022
    Assignee: Monell Chemical Senses Center
    Inventors: Peihua Jiang, Weiwei Lei
  • Diagnosis and treatment of vitiligo
    Patent number: 11278505
    Abstract: Methods of diagnosing and treating vitiligo.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: March 22, 2022
    Assignee: University of Massachusetts
    Inventors: Jillian M. Richmond, John E. Harris, James Pennock Strassner
  • Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
    Patent number: 11279719
    Abstract: Novel C-2-substituted bicyclic compounds of Formula I have been prepared and found to be useful as inhibitors of by inhibiting geranylgeranylation of proteins. The application is directed to these compounds, to compositions comprising these compounds and to their use, in particular as medicaments to cancer and other conditions treatable by inhibiting human geranylgeranylation pyrophosphate hGGPPS activity.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: March 22, 2022
    Inventors: Youla S. Tsantrizos, Michael Sebag
  • Methods of modifying neuronal function by changing intracellular magnesium levels
    Patent number: 11278567
    Abstract: Methods for modifying neuronal functional activity and/or treating a neurological disorder by using agents that raise neuronal intracellular concentration of magnesium are disclosed. Also provided herein are methods of determining the amenability of an individual to treatment for a neurological disorder, by measuring changes in intracellular magnesium concentration.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 22, 2022
    Assignee: Neurocentria, Inc.
    Inventors: Guosong Liu, Hang Zhou
  • Compositions and methods for modulating ABHD2 activity
    Patent number: 11273167
    Abstract: The present disclosure provides compositions and methods of modulating abhydrolase domain-containing protein-2 (ABHD2). The present disclosure provides methods of identifying agents that modulate ABHD2 activity.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: March 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Polina V. Lishko, Yuriy Kirichok, Melissa R. Miller
  • Compounds useful in HIV therapy
    Patent number: 11274102
    Abstract: The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: March 15, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David Favre, Robert G. Ferris, Jun Tang
  • Nitroxyl donors with improved therapeutic index
    Patent number: 11273143
    Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: March 15, 2022
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
  • Process for the preparation of piperine
    Patent number: 11267798
    Abstract: The present application relates to a process for the preparation of piperine of high purity having low concentrations of isomeric impurities.
    Type: Grant
    Filed: October 13, 2018
    Date of Patent: March 8, 2022
    Assignee: CIPLA LIMITED
    Inventors: Manjinder Singh Phull, Dharmaraj Ramachandra Rao, Geena Malhortra, Dilip Ramdas Birari, Sachin Vasant Desai
  • Apelin receptor (APJ) agonists and uses thereof
    Patent number: 11267789
    Abstract: This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: March 8, 2022
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Scott P. Runyon, Rangan Maitra, Sanju Narayanan, James Barnwell Thomas
  • Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease
    Patent number: 11267780
    Abstract: Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: March 8, 2022
    Assignee: The Trustees of Indiana University
    Inventors: Jaipal Singh, Kerry Fowler
  • Dihydrobenzimidazolones for medical treatment
    Patent number: 11254672
    Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: February 22, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
  • Compounds
    Patent number: 11254689
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 22, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Nicolas Willand
  • Combination of isoindolinone derivatives with SGI-110
    Patent number: 11236047
    Abstract: The invention provides a combination comprising: (i) a compound of formula (Io): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 1, 2022
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, John Francis Lyons
  • Process for preparing water soluble forskolin
    Patent number: 11234957
    Abstract: The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and ?-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 1, 2022
    Assignee: SciPharm S.à.r.l
    Inventor: Andreas Kubin